Blinatumomab in pediatric B-acute lymphoblastic leukemia

Area of Science:

• Immunotherapy
• Pediatric Oncology
• Hematologic Malignancies

Background:

• Blinatumomab is a bispecific T-cell engager approved for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
• Its use is increasing in real-world settings, representing a key advancement in precision medicine for pediatric ALL.

Purpose of the Study:

• To review clinical trials of blinatumomab in pediatric patients.
• To emphasize factors influencing clinical efficacy and adverse events.

Main Methods:

• Literature synthesis of selected clinical trials.
• Focus on determinants of efficacy and safety.

Main Results:

• Blinatumomab shows substantial clinical benefits in pediatric R/R B-ALL.
• Efficacy is influenced by tumor burden, T-cell function, CD19 loss, and lineage switch.
• Treatment-related complications include cytokine release syndrome (CRS), neurotoxicity (ICANS), and infections.

Conclusions:

• Blinatumomab is a crucial immunotherapy for pediatric ALL, requiring vigilant monitoring for adverse events.
• Long-term impacts and optimized dosing/combination strategies require further investigation.